Email

Ce: "McInnes, Pamela (NIH/NIAID)" EE ister "Heilman, Carole (NIH/NIAID)" EE oxi. -nih.gov> Subject: RE: Vaccinia Virus Mouse IL-4 Construct Date: Thu, 30 Oct 2003 15:00:31 -0500 Importance: Normal Attachments: ICAAC 2003_MVA_-_final.psd We made a vaccinia-IL-4 virus construct in 1996 for studies of how IL-4 modulates the effector function of CD8+ T cells. Several papers have been published on the use of this construct in mice. Aung S, Tang YW, Graham BS. IL-4 inhibits induction of cytotoxic T lymphocyte activity in mice infected with recombinant vaccinia virus expressing respiratory syncytial virus M2 protein. Journal of Virology 1999; 73:8944-8949. Aung S, Graham BS. Differential regulation of perforin- and FasL-mediated cytotoxicity by IL-4. Journal of Immunology 2000; 164:3487-3493. Johnson TR, Fischer JE, Graham BS. Construction and characterization of recombinant vaccinia viruses coexpressing a respiratory syncytial virus protein and a cytokine. Journal of General Virology 2001; 82:2107-2116. We used the vaccinia-IL-4 construct to challenge mice immunized with MVA. Either one or two doses of MVA protects mice from lethal infection with vaccinia-IL-4 intranasal challenge. They MVA protection is effective even in mice that have been depleted of CD4 or CD8 T cells prior to challenge, or in mice that cannot make functional antibody responses. This work was presented as an abstract at the recent ICAAC meeting in Chicago and the poster is attached. Let me know if you would like any additional information. Barney Barney S. Graham, M.D., Ph.D. Chief, Viral Pathogenesis Laboratory and Clinical Trials Core VRC/NIAID/NIH URL: www.vre.nih.gov